Indian Officials Conditionally Approve $3.2B Ranbaxy Sale
India's antitrust watchdog on Friday cleared the planned $3.2 billion merger of Ranbaxy Laboratories Ltd. and Sun Pharmaceuticals Inc. under the condition that the companies sell off seven products in order...To view the full article, register now.
Already a subscriber? Click here to view full article